Document is current
Any future updates will be listed below
-
Authors
Deng, Yalan https://orcid.org/0000-0002-3954-3243
Zhao, Zilong https://orcid.org/0000-0001-6607-4596
Sheldon, Marisela
Zhao, Yang https://orcid.org/0000-0002-1501-0565
Teng, Hongqi
Martinez, Consuelo
Zhang, Jie
Lin, Chunru https://orcid.org/0000-0002-6473-8229
Sun, Yutong
Yao, Fan https://orcid.org/0000-0002-4393-7296
Curran, Michael A. https://orcid.org/0000-0003-4996-7207
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA166051, R01CA269140)
American Cancer Society (DBG-22-161-01-MM)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (R01AA028791)
Cancer Prevention and Research Institute of Texas (RP220614)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125396)
- License Information
-
More Information
Article History
Received: 10 June 2023
Accepted: 16 July 2024
First Online: 15 August 2024
Competing interests
: H.Z. consults for Flagship Pioneering, Alnylam Pharmaceuticals, Jumble Therapeutics and Chroma Medicines, and serves on the Scientific Advisory Board of Ubiquitix. H.Z. has research support from Chroma Medicines. H.Z. owns stock in Ionis and Madrigal Pharmaceuticals. M.A.C. reports grants, personal fees and an ownership interest in ImmunoGenesis and personal fees from AstraZeneca. The above interests are not directly related to the contents of this paper. The other authors declare no competing interests.
